Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells

Blood Cells, Molecules, and Diseases

Volumn 55, Issue 4, 2015, Pages 336-346

  Pelosi, Elvira ^a   Castelli, Germana ^a   Testa, Ugo ^a  

^a Istituto Suepriore di Sanità   (Italy)

Author keywords

Acute myeloid leukemia; Leukemia; Leukemic stem cells; Stem cells

Indexed keywords

ANTIGEN; ANTILEUKEMIC AGENT; CD123 ANTIGEN; CD305 ANTIGEN; CD32 ANTIGEN; CD33 ANTIGEN; CD366 ANTIGEN; CD371 ANTIGEN; CD47 ANTIGEN; CD96 ANTIGEN; CD99 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; BIOLOGICAL MONITORING; BLOOD CELL; BONE MARROW CELL; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL GROWTH; CELL RENEWAL; CELL SURVIVAL; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; REVIEW; TARGET CELL; TREATMENT RESPONSE; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHENOTYPE;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PHENOTYPE;

EID: 84943557479     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.07.015     Document Type: Review

References (130)

1. Majeti R., Part C.Y., Weissman I.L. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 2007, 1:635-645.
2. Notta F., Doulatov S., Laurenti E., Poeppl A., Jurisica I., Dick J.E. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011, 333:218-221.
3. Prashad S.L., Calvanese V., YaoYao C., Kaiser J., Wang Y., Sasidharan R., et al. GPI-80 defines self-renewal ability in hematopoietic stem cells during human development. Cell Stem Cell 2015, 16:80-87.
4. Laurenti E., Frelin C., Xie S., Ferrari R., Dunant C.F., Zandi S., et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 2015, 16:302-313.
5. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
6. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291.
7. - fraction. Blood 2000, 115:1976-1984.
8. + cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 2000, 116:3907-3922.
9. Goardon N., Marchi E., Atzberger A., Quek L., Schuh A., Soneji S., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19:138-152.
10. Van Rhenen A., Feller N., Kelder A., Westra A.H., Rombouts E., Zweegman S., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 2005, 11:6520-6527.
11. Witte K.E., Ahlers J., Schafer I., André M., Kerst G., Scheel-Walter H.G., et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr. Hematol. Oncol. 2011, 28:91-99.
12. Wouters R., Cucchi D., Kspers G., Schuurhuis G.J., Cloos L. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Expert. Rev. Hematol. 2014, 7:791-805.
13. - cells in acute myeloid leukemia. Blood 2012, 119:3571-3577.
14. - cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome. J. Hematol. Oncol. 2013, 6:85.
15. Terwijn M., Zeijlemaker W., Kelder A., Rutten A.P., Snel A.N., Scholten W.J., et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS ONE 2014, 9:e107587.
16. + cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003, 88:983-992.
17. Zeijlemaker W., Keider A., Wouters R., Valk P.J., Witte B.I., Cloos J., et al. Absence of leukemic CD34+ cells in acute myeloid leukemia if of high prognostic value: a longstanding controversy deciphered. Br. J. Haematol. 2015, (in press).
18. Bakker A.B., van den Oudenrijn S., Bakker A.Q., Feller N., van Meijer M., Bia J.A., et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004, 64:8443-8450.
19. Van Rhenen A., van Dongen G.A., Kalder A., Rombouts E.J., Feller N., Moshaver B., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110:2659-2666.
20. Moshaver B., van Rhenen A., Kelder A., van der Pol M., Terwijn M., Bachas C., et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008, 26:3059-3067.
21. Zhao X., Singh S., Pardoux C., Zhao J., Hsi ED E.D., Abo A., et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 2010, 95:71-78.
22. Zhang H., Luo J., Li Y., Henderson P.T., Wang Y., Wachsmann-Hogiu S., et al. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine 2012, 8:1116-1124.
23. Lu H., Zhou Q., Deshmukh V., Phull H., Ma J., Tardif V., et al. Targeting human C-type lectin-like molecule-1 (CLL-1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew. Chem. Int. Ed. 2014, 53:9841-9845. V.
24. Meyaard L. LAIR and collagens in immune regulation. Immunol. Lett. 2010, 128:26-28.
25. Walk J., Westerlaken G.H., van Uden N.O., Beldeibos M.E., Meyaard L., Bont L.J. Inhibitory receptor expression on neonatal immune cells. Clin. Exp. Immunol. 2012, 169:164-171.
26. Zheng J., Umikawa M., Cui C., Li J., Chen X., Zhang C., et al. Inhibitory receptors bind ANGPTLS and support blood stem cells and leukemia development. Nature 2012, 485:656-660.
27. Deng M., Lu Z., Zheng J., Wan X., Chen X., Hirayasu K., et al. A motif in LILRB2 critical for Angptl2 binding and activation. Blood 2014, 124:924-935.
28. Xiao Y., Jiang Z., Li Y., Ye W., Jia B., Zhang M., et al. ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica 2015, 100:585-594.
29. Lin M., Price E., Boatman S., Hagedorn E., Trampouki E., Satish-chandran S., et al. Angiopoietin-like protein stimulate HSPC development through interaction with Notch receptor signaling. eLIFE 2015, 4:e 05544.
30. Kang X., Lu Z., Cui C., Deng M., Fan Y., Dong B., et al. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukemia development. Nat. Cell Biol. 2015, 17:665-677.
31. Smyth M.J., Martinet L. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 2015, 15:243-254.
32. Chan C.J., Martinet L., Gilfilan S., Sovra-Fonseca-Gulmares F., Chow M.T., Town L., et al. The receptors CD96 and CD22b oppose each other in the regulation of natural killer cell function. Nat. Immunol. 2014, 15:431-438.
33. Hosen N., Park C., Tatsumi N., Oji Y., Sugiyama H., Gramatziki M., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11008-11013.
34. Garg S., Shanmukhaiah C., Marathe S., Mishra P., Babu Rao V., Ghash K., et al. Differential antigen expression and aberrant signaling via PI3K/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia. Eur. J. Haematol. 2015, (in press).
35. Wang X.M., Mai Y., Yu L., Hailiqlguli N.E.M.M.T. CD96 expression on leukemia stem cells in 69 children with acute leukemia. Chin. J. Contemp. Ped. 2013, 15:633-637.
36. Chavez-Gonzalez A., Dorantes-Acosta E., Morena-Lorenzana D., Alvarado-Moreno A., Arriaga-Pizano L., Mayami H. Expression of CD90, CD96, CD117 and CD123 on different hematopoietic cell population from pediatric patients with acute myeloid leukemia. Arch. Med. Res. 2014, 45:343-350.
37. Mohseni Nodehi S., Repp R., Kellner C., Brantigam J., Staudinger M., Schub N., et al. Enhanced ADCC activity of affinity matured and Fc-engineered antibodies directed against the AML stem cell antigen CD96. PLoS ONE 2012, 7:e42426.
38. Standinger M., Humpe A., Gramatzki M. Strategies for purging CD96+ stem cells in vitro and in vivo. Oncoimmunology 2013, 2:e24500.
39. Kikushige Y., Shima T., Takayanagi S.I., Urata S., Miyamoto T., Iwasaki H., et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717.
40. Kikushige Y., Miyamoto T. TIM-3 is a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int. J. Hematol. 2013, 98:627-633.
41. Jan M., Chao M.P., Cha A.C., Alizadeh A.A., Gentles A.J., Weissman I.L., et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5009-5014.
42. ProKhorov A., Gibbs S.F., Sardelli M., Ruegg L., Fasier-Kan E., Varani L., et al. The immune receptor TIM-3 mediates activation of PI3 kinase/mTOR and HIF-1 pathways in human myeloid leukemia cells. Int. J. Biochem. Cell Biol. 2015, 59:11-20.
43. Gao L., Yu S., Zhang X. Hypothesis: Tim-3/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages. Cell Biochem. Biophys. 2014, 70:273-277.
44. Li C., Chen X., Yu X., Zhu Y., Ma C., Xia R., et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. Int. J. Clin. Exp. Pathol. 2014, 7:6880-6888.
45. Gleason M.K., Lennik T.R., McCullar V., Felices M., O'Brien M.S., Cooley S.A. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012, 119:3064-3072.
46. Fogliero V., Goffredo B.M., Filippini P., Masetti R., Bonanno G., Caruso R., et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 2014, 5:2052-2064.
47. Fogliero V., Cifaldi L., Li Pira G., Goffredo B.M., Vita L., Locatelli F. TIM-3/Gal-9 interaction induces IFNγ dependent IDO1 expression in acute myeloid leukemia blast cells. J. Hematol. Oncol. 2015, 8:36.
48. Zhou Q., Munger M.E., Veenstra R.G., Wegel B.J., Hiroshima M., Munn D.H., et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011, 117:4501-4510.
49. Anderson A.C. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2014, 2:393-398.
50. Jan M., Snyder T., Corces-Zimmerman R., Vyas P., Weissman I.L., Quake S.R., et al. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 2012, 4. (149ra118).
51. Corces-Zimmerman R., Hong W.J., Weissman I.L., Medliros B.C., Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulatory and persist in remission. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:2548-2553.
52. Sato N., Caux C., Kitamura T., Watanabe Y., Arai K., Banchereau J., Miyajima A., et al. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood 1993, 82(3):752-761.
53. + hemopoietic cells. Leuk. Lymphoma 1996, 24:11-25.
54. + hematopoietic cells from different tissues. Stem Cells 1999, 17:265-272.
55. Manz M.G., Miyamoto T., Akashi K., Weissman I.L. Prospective isolation of human clonogenic common myeloid progenitors. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11872-11877.
56. Taussig D.C., Pearce D.J., Simpson C., Rohatiner A.Z., Lister T.A., Kelly G., et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 106:4086-4092.
57. Jin L., Lee E.M., Ramshaw H.S., Busfiled S.J., Peoppl A.G., Wilkinson L., Guthridge M.A., Thomas D., Barry E.F., Boyd A., Gearing D.P., Vairo G., Lopez A.F., Dick J.E., Lock R.B. Monoclonal-antibody mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemia stem cells. Cell Stem Cell 2009, 5(1):31-42.
58. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., Meyerrose T., Rossi R., Grimes B., Rizzieri D.A., Luger S.M., Phillips G.L. The interleukin-3 receptor alpha is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14(10):1777-1784.
59. Munoz L., Nomdedeu J.F., Lopez O., Cornier M.J., Bellido M., Aventin A., Brunet S., Sierra J. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001, 86(12):1261-1269.
60. Testa U., Riccioni R., Coccia E., Stellacci E., Samoggia P., Latagliata R., Mariani G., Rossini A., Battistini A., Lo-Coco F., Peschle C. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity and poor prognosis. Blood 2002, 100(8):2980-2988.
61. Testa U., Riccioni R., Diverio D., Rossini A., Lo-Coco F., Peschle C. Interleukin 3 receptor in acute leukemia. Leukemia 2004, 18(2):219-226.
62. Riccioni R., Diverio D., Riti V., Buffolino S., Mariani G., Boe A., Cedrone M., Ottone T., Foà R., Testa U. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukemias with mutated FMS-related tyrosine kinase 3 receptor. Br. J. Haematol. 2009, 144(3):376-387.
63. Rollins-Raval M., Pillai R., Mitsuhashi-Warita T., Metha R., Boyadzisn M., Djokic M., Roth C. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl. Immunohistochem. Mol. Morphol. 2013, 21(3):212-217.
64. Gonen M., Sun Z., Figueroa M.A., Patel J.P., Abdel-Waheb O., Racevskis J., Ketterling R.P., Fernandez H., Rowe J.M., Tallman M.S., Melnick A., Levine R.L., Paietta E. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012, 120(11):2297-2306.
65. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., Jordan C.T. Nuclear factor-kappa B is constitutively activated in primitive acute human acute myelogenous leukemia cells. Blood 2011, 98(8):2301-2307.
66. Hwang K., Park C.J., Jang S., Chi H.S., Kim D.Y., Lee J.H., Im H.J., Seo J.J. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann. Hematol. 2012, 91(10):1541-1546.
67. + blasts are predictive of an adverse outcome in acute myeloid leukemia. Haematologica 2011, 96:1792-1798. V.
68. - stem cells defines leukemia-initiating cells in Fanconi anemia AML. Blood 2011, 117(16):4243-4252.
69. Larsen H.O., Roug A.S., Just J., Brown G.D., Hokland P. Expression of the hMICL in acute myeloid leukemia - a highly reliable disease marker at diagnosis and during follow-up. Cytometry 2012, 82(1):3-8.
70. Roug A.S., Larsen H.O., Nedeiby L., Just T., Brown G., Nyvold C., Ommen H., Hokland P. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukemia. Br. J. Haematol. 2014, 164(1):212-222.
71. Nederby L., Hokland P., Brown G., Hansen M., Nyvold C.G., Roug A.S. Unraveling the leukemic nature of hMICL and CD123 expressing cells in acute myeloid leukemia. Blood 2013, 122:2626. (Abstract).
72. Han L., Jorgensen J.L., Wang S.A., Huang X., Gonzalez G.N., Brooks C., Rowinsky E., Levis M., Zhou J., Ciurea S.O., Alatrash G., Cortes J.E., Kantarjian H.M., Andreef M., Ravandi F., Konopleva M. Leukemia stem cell marker CD123 (IL-3R alpha) predicts minimal residual disease and relapse, providing a valid target for SL-101 in acute myeloid leukemia with FLT3-ITD mutations. Blood 2013, 122:359. (Abstract).
73. Testa U., Pelosi E., Frankel A. CD123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker Res. 2014, 2:4.
74. Frankel A.E., McCubrey J.A., Miller M.S., Delatte S., Ramage J., Kiser M., Kucera G.L., Alexander R.L., Beran M., Tagge E.P., Kreitman R.J., Hogge D.E. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000, 14(4):576-585.
75. Testa U., Riccioni R., Biffoni M., Diverio D., Lo-Coco F., Foà R., Peschle C., Frankel A. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 2005, 106(7):2527-2529.
76. Yalcintepe L., Frankel A.E., Hogge D.E. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 2006, 108(10):3530-3537.
77. Hogge D.E., Yalcintepe L., Wong S.H., Gerhard B., Frankel A.E. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin. Cancer Res. 2006, 12(4):1284-1291.
78. 388) linked to human interleukin 3 (IL3) in cynomolgus monkeys. Leuk. Lymphoma 2004, 45(9):1647-1656.
79. Busfield S.J., Biondo M., Wong M., Ramshaw H.S., Lee E.M., Ghosh S., et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia 2014, 28:2213-2231.
80. Lee E.M., Yee D., Busfield S.J., McManus J.F., Cummings N., Vairo G., et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica 2015, 100:914-926.
81. Kuo S.R., Wong L., Liu J.S. Engineering of a CD123×CD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng. Des. Sel. 2012, 25(7):561-569.
82. Chicili G.R., Huang L., Li H., Tang Q., Jin L., Gorlatov S., et al. A CD3×CD123 bispecific DART for redirecting host T cell to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci. Transl. Med. 2015, 7. (289ra82).
83. Stein C., Kellner C., Kugler M., Reiff N., Mentz K., Schwenkert M., Stockmeyer B., Mackensen A., Fey G.H. Novel conjugates of single chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukemia cells. Br. J. Haematol. 2010, 148(6):879-889.
84. Kugler M., Stein C., Kellner C., Mentz K., Saul D., Schwenvert M., Schubert I., Singer H., Oduncu F., Stockmeyer B., Mackensen A., Fey G.H. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukemia cells by dual targeting. Br. J. Haematol. 2010, 150(5):574-586.
85. Ehninger A., Kramert M., Rolling C., Thiede C., Bornhauser M., von Bonin M., et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014, 4:e218.
86. Tettamanti S., Marin V., Pizzitola I., Magnani C., Giordano Attianese G., Cribioli E., Cribioli E., Maltese F., Galimberti S., Lopez A.F., Biondi A., Bonnet D., Biagi E. Targeting of acute myeloid leukemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br. J. Haematol. 2013, 161(3):389-401.
87. Mardiros A., Dos Santos C., McDonald T., Brown C.E., Wang X., Budde L.E., Hoffman L., Aguilar B., Chang W.C., Bretzlaff W., Chang B., Jonnalagadda M., Starr R., Ostberg J.R., Jensen M.C., Bhatia R., Jj Forman S. T cells expressing CD123-specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia. Blood 2013, 122:3138-3148.
88. Gill S., Tasian S.K., Ruella M., Shestova O., Li Y., Porter D.L., et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014, 123:2343-2354.
89. Frankel A.E., Konopleva M., Hogge D., Rizzieri D., Brooks C., Cirrito T., et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. J. Clin. Oncol. 2013, 31(Suppl.: abstract nr):7029.
90. Frankel A.E., Woo J.H., Ahn C., Pemmaraju N., Medeiros B.C., Carraway H.E., et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014, 124:385-392.
91. He S.Z., Busfield S., Ritchie D.S., Hertzberg M.S., Durrant S., Lewis I.D., et al. A phase I study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL 360 in relapsed refractory or high-risk acute myeloid leukemia. Leuk. Lymphoma 2015, 56:1406-1415.
92. Douglas-Smith B., Roboz G.L., Walter R.B., Altman J.K., Ferguson A., Curcio T.J., et al. First in man, phase 1 study of CSL362 (anti-IL3Rα/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood 2014, (ASH Meeting, Abst. 120).
93. Frolova O., Benito J., Brooks C., Wang R.Y., Korchin B., Rowinsky E.K., et al. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukemic cells and stem cells in advanced phase chronic myeloid leukemia. Br. J. Haematol. 2014, 166:862-874.
94. Pardanani A., Lasho T., Chen D., Kimlinger T.K., Finke C., Zblewski D., et al. Aberrant expression of CD123 (interleukin-3 receptor-alpha) on neoplastic mast cells. Leukemia 2015, 29:1605-1608.
95. Krupka C., Kufer P., Kischel R., Zugmaier G., Bogeholz J., Kohnke T., et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014, 123:356-365.
96. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. acute myeloid leukemia stem cells and CD33- targeted Immunotherapy. Blood 2012, 119:6198-6208.
97. Patersdorf S.H., Kopecky K.J., Slovak M., Willman C., Nevill T., Brandwein J. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121:4854-4860.
98. Burnatt A.K., Hills R.K., Milligan D., Kjeldsen L., Kell J., Russell N.H., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 2011, 29(29):369-377.
99. Liehtenegger F.S., Krupka C., Köhnke T., Subklewe M. Immunotherapy for acute myeloid leukemia. Semin. Hematol. 2015, 52:207-214.
100. Hills R.K., Castigne S., Applelbaum F.R., Delaunay J., Petersdorf S., Orthus M., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: a meta-analysis of individual patient data from randomized controlled trials. Lancet Oncol. 2014, 15:986-996.
101. Laszlo G.S., Estey E.H., Walter R.B. The past future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014, 28:143-153.
102. Kung Sutherland M., Walter R.B., Jeffray J.C., Burke P.J., Yu C., Kostner H., et al. SGN-CD33A: a novel targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013, 122:1455-1463.
103. Stein E.M., Stein A., Walter R.B., Fathi A.T., Lancet J.E., Kovacsovics T.J., Stein E.M., Stein A., Walter R.B., Fathi A.T., Lancet J.E., Kovacsovics T.J., et al. Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia. ASH Meeting 2014, 623. (abst.).
104. - bispecific BITE antibody construct. Leukemia 2013, 27:1107-1115.
105. Laszlo G.S., Gudgeon C.J., Harrington K.H., Dell'Arringa J., Newhall K.J., Means G.D., et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BITE) antibody, AMG 330, against human AML. Blood 2014, 123:554-561.
106. Harrington K.H., Gudgeon C.J., Laszlo G.S., Newhall K.J., Sinclair A.M., et al. The broad activity of the CD33/CD3 bispecific BITE antibody AMG 330 in primary human AML is impacted by disease stage and cytogenetic/molecular risk. ASH Meeting 2014, 266. (abst.).
107. Friedrich M., Henn A., Raum T., Baytus M., Matthes K., Hendrich L., et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol. Cancer Ther. 2014, 13:1549-1557.
108. o'Hear C., Heiber J.F., Schubert I., Fey G., Geiger T.L. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 2015, 100:336-344.
109. Kenederian S.S., Ruella M., Schestova O., Klichinsky M., Aikava V., Morissette J.J.D., et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 2015, (in press).
110. Ghffari S.F., Smadja-Jaffe F., Oostendorp R., Lévesque J.P., Dougherty G., Eaves A., et al. CD44 isoform in normal and leukemic hematopoiesis. Exp. Hematol. 1999, 27:978-993.
111. Lapidot T.A., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
112. Jim L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.
113. - stem cells in various myeloid malignancies. Leuk. Lymphoma 2006, 47:207-222.
114. Hwang K., Park C.J., Jang S., Chi H.S., Kim D.Y., Lee J.H., et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann. Hematol. 2012, 91:1541-1546.
115. 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: prelude to phase 1 clinical studies. Mabs 2014, 6:567-575.
116. Barclay A.N. Signal regulatory protein alpha (SIRPalpha)/CD47 interaction and function. Curr. Opin. Immunol. 2009, 21:47-52.
117. Sick E., Jeanne A., Schneider C., Dedieu S., Takeda K., Martiny L. CD47 update: a multifaceted actor in the tumor microenvironment of potential therapeutic interest. Br. J. Pharmacol. 2012, 167:1415-1430.
118. Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
119. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiwal S., Gibbs K.D., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286-299.
120. Pang W.W., Pluvinage J.V., Price E.A., Sridhar K., Arber D.A., Greenberg P.L., et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3011-3016.
121. Theochaqrides A.P., Jin L., Cheng P.Y., Prasolava T.K., Malko A.V., Ho J.M., et al. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J. Exp. Med. 2012, 209:1833-1899.
122. Bonardi F., Fusetti F., Deelen P., van Gosliga D., Vellenga E., Schuringa J. A proteomics and transcriptomics approach to identify leukemic stem cells (LSC) markers. Mol. Cell. Proteomics 2013, 12:626-637.
123. Zhang P.J., Barcos M., Stewart C.C., Block A.W., Sait S., Brooks J.J. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related disease. Mof Pathol. 2000, 13:452-458.
124. Angelini O.F., Ottone T., Guerrera G., Lavorgna S., Cittadini M., Buccisano F., Angelini O.F., Ottone T., Guerrera G., Lavorgna S., Cittadini M., Buccisano F., et al. A Leukemia-associated CD34/CD123/CD25/CD99-positive Immunophenotype Identifies FLT3-mutated Clones in Acute Myeloid Leukemia 2015, (in press).
125. Saito Y., Kitamura H., Hijikata A., Tomizawa-Murosawa M., Tanaka S., Takagi S., et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2010, 2:17ra9.
126. Cerny J., Yu H., Ramanathan M., Walsh W.V., Fortier N., Shanahan L., et al. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia. Br. J. Haematol. 2013, 160:262-266.
127. Guo Z., Wang A., Zhang W., Levit M., Gao Q., Barberis C., et al. CD25-positive AML cells through concomitant Suppression of Stat5 activation and degradation of Myc oncogene. Blood 2014, 124:1777-1789.
128. Schepers H., van Gosliga D., Wierenga A.T., Eggen B.J., Schuringa J.J., Vellenga E. STAT5 is required for long-term maintenance of normal and leukemic stem/progenitor cells. Blood 2007, 110:2880-2888.
129. King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Nitziachristos P., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153:1552-1566.
130. Schinke C., Giricz O., Li W., Shastri A., Gordon S., Barreyro L., et al. IL-8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood 2015, 125:3144-3152.